NCT05084950

Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 10,000 (estimated)
• Sponsor: Centre Scientifique de Monaco · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.

Detailed description

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Conditions

• SARS-CoV-2
• COVID-19
• Vaccines
• Antibody

Timeline

• Start date: 2021-07-01
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2021-10-20
• Last updated: 2021-10-20

Locations

1 site across 1 country: Monaco